-
## Introduction
In [this section about the modality agnostic phenotypic data](https://bids-specification.readthedocs.io/en/stable/03-modality-agnostic-files.html#phenotypic-and-assessment-data), th…
-
This issue relates to Green/Gamma's efforts on Workflow 4.
-
Can make it and/or "signs and symptoms" (GENEPIO_0001523)) about
"symptom" (SYMP_0000462) and perhaps "Clinical Findings Indicator" (NCIT_C181043)) for signs.
-
Last class we talked about adding two different graphs, so aren't other operations such as graph subtraction and graph products possible as well? For example, if we were to select particular features…
-
While looking at bringing in multi-term phenotypes for #418, I noticed that SGD included chemical condition data in their files. Which brought up the question for me of whether we should include g2p a…
-
Thus far, most phenotype ontologies have focused on abnormal phenotypes, often refined with qualitative assertions about whether an abnormality involves higher or lower levels of some phenotypic quali…
-
Andy Crouse reported an issue where very un-pathway-like things are being returned when querying for `biolink:Pathway`s associated with a disease. See this query: https://arax.ncats.io/?r=41416
It …
-
`imagine in your mind a planet looks like earth. we call it (R2) planet. it has mountains, oceans, jungles and a lot of natural resources. now, imagine a part of planet R2 , with high rocky mountains,…
-
https://arax.ncats.io/?source=ARS&id=0445a10f-05b6-4bf3-82a5-586a55655e1c
-
Include:
- new disease terms or updates to DO's disease terms
there is a group of disorders termed 'RNA exosomopathies', which arise from pathogenic variants in RNA exosome genes
- include the…